Pharmaceutical

The privileged status of orphan medicines in Germany

In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.

Apr 27, 2024 - 00:00
The privileged status of orphan medicines in Germany
In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.
Read the original article

Tags:

Previous Article

Pioneer Institute study finds IRA discourages non-opioid drug innovation

Next Article

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price t...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Manufacturers say bird flu shots for humans can be made quickly; obesity guidelines for children disappoint

STAT+: Pharmalittle: Manufacturers say bird flu shots f...

Mar 20, 2023

Opinion: The amoxicillin shortage continues to force pediatricians and families to scramble

Opinion: The amoxicillin shortage continues to force pe...

May 9, 2023

STAT+: Liver disease researchers are hoping AI can improve their trial design

STAT+: Liver disease researchers are hoping AI can impr...

Apr 7, 2023